Your browser doesn't support javascript.
loading
Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma.
Kang, Yubin; Sundaramoorthy, Pasupathi; Gasparetto, Cristina; Feinberg, Daniel; Fan, Shengjun; Long, Gwynn; Sellars, Emily; Garrett, Anderson; Tuchman, Sascha A; Reeves, Brandi N; Li, Zhiguo; Liu, Bei; Ogretmen, Besim; Maines, Lynn; Ben-Yair, Vered Katz; Smith, Charles; Plasse, Terry.
  • Kang Y; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Suite 5000, Durham, NC, DUMC 396127710, USA. yubin.kang@duke.edu.
  • Sundaramoorthy P; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Suite 5000, Durham, NC, DUMC 396127710, USA.
  • Gasparetto C; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Suite 5000, Durham, NC, DUMC 396127710, USA.
  • Feinberg D; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Suite 5000, Durham, NC, DUMC 396127710, USA.
  • Fan S; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Suite 5000, Durham, NC, DUMC 396127710, USA.
  • Long G; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Suite 5000, Durham, NC, DUMC 396127710, USA.
  • Sellars E; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Suite 5000, Durham, NC, DUMC 396127710, USA.
  • Garrett A; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, 2400 Pratt Street, Suite 5000, Durham, NC, DUMC 396127710, USA.
  • Tuchman SA; Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Reeves BN; Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
  • Li Z; Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA.
  • Liu B; Division of Hematology, Department of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
  • Ogretmen B; Department of Biochemistry and Molecular Biology, and Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
  • Maines L; Apogee Biotechnology Corporation, Hummelstown, PA, USA.
  • Ben-Yair VK; RedHill Biopharma, Tel Aviv, Israel.
  • Smith C; Apogee Biotechnology Corporation, Hummelstown, PA, USA.
  • Plasse T; RedHill Biopharma, Tel Aviv, Israel.
Ann Hematol ; 102(2): 369-383, 2023 Feb.
Article en En | MEDLINE | ID: mdl-36460794
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Mieloma Múltiple Límite: Animals / Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Mieloma Múltiple Límite: Animals / Humans Idioma: En Año: 2023 Tipo del documento: Article